In this <i>Opinion</i> article, we confront the role of artificial intelligence (AI) in targeting and understanding resistance to targeted therapy using the most frequently mutated oncoprotein family in human cancer, rat sarcoma virus guanosine triphosphate hydrolases (RAS GTPases), here Kirsten RAS (KRAS), as an example. This evidence concerns the gene KRAS and cancer.